DUBLIN, Jan. 12, 2017 /PRNewswire/ -- Allergan plc (NYSE:
AGN) today announced that it intends to release fourth quarter and
full year 2016 financial results on Wednesday, February 8, 2017, prior to the open of
U.S. financial markets. The Company will also provide revenue and
certain additional financial metrics guidance for full year
2017.
The Company will host a conference call and webcast at
8:30 a.m. Eastern Standard Time on
Wednesday, February 8, 2017 to
discuss its financial results. The dial-in number to access the
call is U.S./Canada (877)
251-7980, International (716) 803-8252, and the conference ID is
50941900.
A taped replay of the conference call will also be available
beginning approximately two hours after the call's conclusion and
will remain available through 11:30 PM
Eastern Time on April 8, 2017.
The replay may be accessed by dialing (855) 859-2056 and entering
conference ID 50941900. From international locations, the replay
may be accessed by dialing (404) 537-3406 and entering the same
conference ID. To access the webcast, go to Allergan's Investor
Relations Web site at http://ir.allergan.com. A replay of the
webcast will also be available.
About Allergan plc
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global
pharmaceutical company and a leader in a new industry model –
Growth Pharma. Allergan is focused on developing,
manufacturing and commercializing branded pharmaceuticals, devices
and biologic products for patients around the world.
Allergan markets a portfolio of leading brands and best-in-class
products for the central nervous system, eye care, medical
aesthetics and dermatology, gastroenterology, women's health,
urology and anti-infective therapeutic categories.
Allergan is an industry leader in Open Science, the Company's
R&D model, which defines Allergan's approach to identifying and
developing game-changing ideas and innovation for better patient
care. This approach has led to Allergan building one of the
broadest development pipelines in the pharmaceutical industry with
70+ mid-to-late stage pipeline programs in development.
Our Company's success is powered by our more than 15,000 global
colleagues' commitment to being Bold for Life. Together, we build
bridges, power ideas, act fast and drive results for our customers
and patients around the world by always doing what it is right.
With commercial operations in approximately 100 countries,
Allergan is committed to working with physicians, healthcare
providers and patients to deliver innovative and meaningful
treatments that help people around the world live healthier lives
every day.
For more information, visit Allergan's website at
www.Allergan.com.
Forward-Looking Statement
Statements contained in this press release that refer to future
events or other non-historical facts are forward-looking statements
that reflect Allergan's current perspective of existing trends and
information as of the date of this release. Except as expressly
required by law, Allergan disclaims any intent or obligation to
update these forward-looking statements. Actual results may differ
materially from Allergan's current expectations depending upon a
number of factors affecting Allergan's business. These factors
include, among others, the difficulty of predicting the timing or
outcome of FDA approvals or actions, if any; the impact of
competitive products and pricing; market acceptance of and
continued demand for Allergan's products; difficulties or delays in
manufacturing; and other risks and uncertainties detailed in
Allergan's periodic public filings with the Securities and Exchange
Commission, including but not limited to Allergan's Annual Report
on Form 10-K for the year ended December 31,
2015 and Quarterly Report on Form 10-Q for the quarter ended
September 30, 2016 (certain of such
periodic public filings having been filed under the "Actavis plc"
name). Except as expressly required by law, Allergan disclaims any
intent or obligation to update these forward-looking
statements.
CONTACTS:
Investors:
Lisa
DeFrancesco
(862) 261-7152
Media:
Mark Marmur
(862) 261-7558
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/allergan-to-report-fourth-quarter-and-full-year-2016-earnings-and-host-conference-call-and-webcast-300390006.html
SOURCE Allergan plc